AU2013224027B2 - Chromatographic isolation of cells and other complex biological materials - Google Patents

Chromatographic isolation of cells and other complex biological materials Download PDF

Info

Publication number
AU2013224027B2
AU2013224027B2 AU2013224027A AU2013224027A AU2013224027B2 AU 2013224027 B2 AU2013224027 B2 AU 2013224027B2 AU 2013224027 A AU2013224027 A AU 2013224027A AU 2013224027 A AU2013224027 A AU 2013224027A AU 2013224027 B2 AU2013224027 B2 AU 2013224027B2
Authority
AU
Australia
Prior art keywords
binding
reagent
receptor
affinity
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013224027A
Other languages
English (en)
Other versions
AU2013224027A1 (en
Inventor
Herbert Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juno Therapeutics GmbH
Original Assignee
Juno Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics GmbH filed Critical Juno Therapeutics GmbH
Publication of AU2013224027A1 publication Critical patent/AU2013224027A1/en
Assigned to JUNO THERAPEUTICS GMBH reassignment JUNO THERAPEUTICS GMBH Amend patent request/document other than specification (104) Assignors: STAGE CELL THERAPEUTICS GMBH
Priority to AU2019200178A priority Critical patent/AU2019200178B2/en
Application granted granted Critical
Publication of AU2013224027B2 publication Critical patent/AU2013224027B2/en
Priority to AU2021282451A priority patent/AU2021282451B2/en
Priority to AU2025200426A priority patent/AU2025200426A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013224027A 2012-02-23 2013-02-25 Chromatographic isolation of cells and other complex biological materials Active AU2013224027B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019200178A AU2019200178B2 (en) 2012-02-23 2019-01-11 Chromatographic isolation of cells and other complex biological materials
AU2021282451A AU2021282451B2 (en) 2012-02-23 2021-12-08 Chromatographic isolation of cells and other complex biological materials
AU2025200426A AU2025200426A1 (en) 2012-02-23 2025-01-22 Chromatographic isolation of cells and other complex biological materials

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602150P 2012-02-23 2012-02-23
US61/602,150 2012-02-23
PCT/EP2013/053650 WO2013124474A2 (en) 2012-02-23 2013-02-25 Chromatographic isolation of cells and other complex biological materials

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200178A Division AU2019200178B2 (en) 2012-02-23 2019-01-11 Chromatographic isolation of cells and other complex biological materials

Publications (2)

Publication Number Publication Date
AU2013224027A1 AU2013224027A1 (en) 2014-10-02
AU2013224027B2 true AU2013224027B2 (en) 2019-01-24

Family

ID=47891608

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013224027A Active AU2013224027B2 (en) 2012-02-23 2013-02-25 Chromatographic isolation of cells and other complex biological materials
AU2019200178A Active AU2019200178B2 (en) 2012-02-23 2019-01-11 Chromatographic isolation of cells and other complex biological materials
AU2021282451A Active AU2021282451B2 (en) 2012-02-23 2021-12-08 Chromatographic isolation of cells and other complex biological materials
AU2025200426A Pending AU2025200426A1 (en) 2012-02-23 2025-01-22 Chromatographic isolation of cells and other complex biological materials

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019200178A Active AU2019200178B2 (en) 2012-02-23 2019-01-11 Chromatographic isolation of cells and other complex biological materials
AU2021282451A Active AU2021282451B2 (en) 2012-02-23 2021-12-08 Chromatographic isolation of cells and other complex biological materials
AU2025200426A Pending AU2025200426A1 (en) 2012-02-23 2025-01-22 Chromatographic isolation of cells and other complex biological materials

Country Status (11)

Country Link
US (4) US10228312B2 (enExample)
EP (2) EP4545964A3 (enExample)
JP (4) JP6362543B2 (enExample)
CN (2) CN106940268B (enExample)
AU (4) AU2013224027B2 (enExample)
CA (1) CA2865033C (enExample)
ES (1) ES3011307T3 (enExample)
IN (1) IN2014DN06475A (enExample)
RU (1) RU2746407C1 (enExample)
SG (2) SG10201606970UA (enExample)
WO (1) WO2013124474A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154048A1 (en) * 2014-04-03 2015-10-08 Gjerde Douglas T Devices and methods for purification, detection and use of biological cells
US9637719B2 (en) 2013-12-06 2017-05-02 Douglas T. Gjerde Devices and methods for purification of biological cells
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
MX386422B (es) 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
MY184699A (en) 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
AU2015254588B2 (en) * 2014-04-30 2020-05-21 Iba Gmbh Method of isolating a target cell
EP2955521A1 (en) * 2014-06-11 2015-12-16 Centre Hospitalier Universitaire Vaudois (CHUV) Methods for separating cells
WO2016073602A2 (en) * 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Methods for transduction and cell processing
DE202014105965U1 (de) 2014-12-10 2015-01-26 Cell.Copedia GmbH Spritzengehäuse zum Pipettieren eines biologischen Materials mit integrierten Membranen
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
CN105606815A (zh) * 2015-05-18 2016-05-25 烟台载通生物技术有限公司 一种用于免疫检测的多单元装置
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) * 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN108474002B (zh) 2015-10-22 2023-05-23 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
GB201521784D0 (en) 2015-12-10 2016-01-27 Univ Birmingham Cell purification
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
WO2018112557A1 (en) * 2016-12-23 2018-06-28 Altnia Operations Pty Ltd Methods and compositions for purification or isolation of microvesicles and exosomes
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
SG11201909931PA (en) * 2017-04-27 2019-11-28 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
BR112020001719A2 (pt) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagentes para expansão de células que expressam receptores recombinantes
MX2020001490A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
PL3704230T3 (pl) 2017-11-01 2025-02-24 Juno Therapeutics, Inc. Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
EP3731947B1 (en) 2017-12-29 2023-03-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Purification and labeling of extracellular vesicles using a mixed mode resin composition
WO2019183334A1 (en) * 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
EA202190022A1 (ru) 2018-06-18 2021-03-18 Эксофарм Лимитид Способы и композиции для очистки или выделения микровезикул и экзосом
KR20210031927A (ko) * 2018-07-17 2021-03-23 유니버시티 오브 워싱톤 압타머 기반 가역적 세포 선택과 관련된 조성물 및 방법
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
US12366580B2 (en) 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
JP7582940B2 (ja) 2018-10-31 2024-11-13 ジュノ セラピューティクス ゲーエムベーハー 細胞の選択および刺激のための方法ならびにそのための装置
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
AU2020287882A1 (en) 2019-06-07 2022-01-20 Juno Therapeutics, Inc. Automated T cell culture
JP2022538125A (ja) * 2019-06-27 2022-08-31 バイオイミュネイト テクノロジーズ リミテッド 多発性硬化症関連ｔ細胞の除去のためのフィルター
US12444491B2 (en) 2019-08-30 2025-10-14 Juno Therapeutics, Inc. Machine learning methods for classifying cells
CN114502717A (zh) * 2019-08-30 2022-05-13 弗洛设计声能学公司 多靶受体的声学亲和细胞选择
CN114555204A (zh) * 2019-09-10 2022-05-27 皮尔斯生物科技有限公司 样品制备组合物、装置、系统和方法
CN114929360A (zh) 2019-10-30 2022-08-19 朱诺治疗学有限公司 细胞选择和/或刺激装置及使用方法
US20230019849A1 (en) * 2019-12-09 2023-01-19 St. Jude Children's Research Hospital, Inc. Method for Preparing CD7-Negative, CD3-Positive T Cells
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
US11965882B2 (en) 2020-01-31 2024-04-23 Cell.Copedia GmbH Methods of isolating a biological entity
BR112022015968A2 (pt) 2020-02-12 2022-10-11 Juno Therapeutics Inc Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas
CN115768443A (zh) 2020-02-12 2023-03-07 朱诺治疗学股份有限公司 Cd19定向嵌合抗原受体t细胞组合物和方法及其用途
JP2023526278A (ja) 2020-05-13 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
WO2023017115A1 (en) * 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
EP4223381B1 (en) * 2022-02-02 2025-04-02 Sartorius BIA Separations d.o.o. Method of purifying or removing a target component from full plasma
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2025049247A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049254A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049250A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049253A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
WO2025083196A1 (en) 2023-10-18 2025-04-24 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices
US12434218B2 (en) 2023-11-28 2025-10-07 Phenomenex, Inc. Pore structure for separation of adeno-associated viruses (AAVS) from their aggregates
US20250241912A1 (en) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
WO2025179188A1 (en) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
WO2025235851A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255004A1 (en) * 2006-11-15 2008-10-16 Invitrogen Dynal As Methods of reversibly binding a biotin compound to a support

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2467434A (en) 1947-05-10 1949-04-19 Air Associates Inc Servomotor and pressure responsive valve therefor
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3583940D1 (de) 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
DE69534880T2 (de) 1994-07-29 2007-02-22 Sunol Molecular Corp., Miramar Mhc-komplexe und verwendungen davon
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
JPH11501008A (ja) 1995-02-09 1999-01-26 ユニバーシティ オブ ワシントン 改変−アフィニティーストレプトアビジン
CA2222035A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
US5629205A (en) 1995-05-19 1997-05-13 Allelix Biopharmaceuticals Inc. Promoters for gene expression
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US5773224A (en) 1996-02-12 1998-06-30 Grandics; Peter Immunoselection system for cell elution
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
NZ333915A (en) 1996-08-16 2000-11-24 Harvard College Soluble monovalent and multivalent MHC class II fusion proteins
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
JP2001514524A (ja) 1997-03-14 2001-09-11 トラスティーズ オブ ボストン ユニバーシティー マルチフレイバーストレプトアビジン
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
ES2323098T3 (es) 1997-09-16 2009-07-06 Oregon Health And Science University Moleculas de mhc recombinantes utiles para la manipulacion de celulas t especificas de antigeno.
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US5985658A (en) * 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
IL137706A0 (en) 1998-02-19 2001-10-31 Harvard College Mhc fusion proteins and conjugates
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
WO2000046349A1 (en) 1999-02-04 2000-08-10 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP1048732A1 (de) 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen
US6849185B1 (en) 1999-05-14 2005-02-01 Pall Corp Charged membrane
WO2000069549A1 (en) 1999-05-14 2000-11-23 Pall Corporation Charged membrane
EP1669129A1 (en) 1999-05-14 2006-06-14 Pall Corporation Charged membrane
AU783233B2 (en) 1999-06-07 2005-10-06 Tet Systems Holding Gmbh & Co. Kg Novel TET repressor-based transcriptional regulatory proteins
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
ES2283399T3 (es) 2000-04-25 2007-11-01 Otsuka Pharmaceutical Co., Ltd. Peptidomimetico de gd3.
US6638728B1 (en) 2000-06-16 2003-10-28 Pierce Biotechnology, Inc. Coated surfaces with high capacity for capturing target molecules
ES2324645T3 (es) 2000-11-03 2009-08-12 Genentech, Inc. Cambios de tasa metabolica en fermentaciones que expresen proteinas recombinantes.
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
EP1349569B1 (en) 2001-01-12 2007-04-18 Becton Dickinson and Company Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof
GB0102568D0 (en) 2001-02-01 2001-03-21 Magnetic Biosolutions Sweden A Method
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
ATE382053T1 (de) 2001-08-27 2008-01-15 Genentech Inc System zur antikörperexpression und- synthese
EP1908769A1 (en) 2001-08-27 2008-04-09 Genentech, Inc. A system for antibody expression and assembly
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
EP1481004B1 (de) * 2002-03-01 2009-12-02 Volker A. Erdmann Streptavidin-bindungspeptid
US7754155B2 (en) * 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
WO2003090781A1 (en) 2002-04-23 2003-11-06 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
RU2344425C2 (ru) 2002-06-24 2009-01-20 Профос АГ Способ идентификации и экстракции эндотоксина
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
EP1532167B1 (en) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
JP2006501449A (ja) 2002-09-27 2006-01-12 ザ ジェネラル ホスピタル コーポレーション 細胞分離のためのマイクロ流体デバイスおよびその使用
US7112439B2 (en) 2003-01-09 2006-09-26 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
JP2006525013A (ja) 2003-05-02 2006-11-09 インセプション バイオサイエンス インコーポレイティッド 血液幹細胞の数の増幅のための装置および方法
DK1623017T3 (da) 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
EP1656455B1 (en) 2003-08-13 2012-09-19 Sandoz Ag Process for the purification of recombinant polypeptides
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
GB2408507B (en) 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
KR100570422B1 (ko) 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
JP2007512528A (ja) * 2003-11-20 2007-05-17 バイオセンサー、アプリケーションズ、スエーデン、アクチボラグ 所定の抗原混合物に特異的な少なくとも２種類の異なる抗体の混合物およびその混合物の使用
EP2336153B1 (en) 2003-11-21 2016-03-30 Pfenex Inc. Improved expression systems with SEC-system secretion
SE0400181D0 (sv) * 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
SI1733037T1 (sl) 2004-03-11 2015-02-27 Genentech, Inc. Postopek za izdelavo polipeptidov
EP1766400B1 (en) * 2004-06-03 2009-04-15 Meso Scale Technologies, LLC Methods for conducting whole blood assays
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
CN101044405B (zh) * 2004-10-15 2015-06-10 金克克国际有限公司 竞争性示差筛选
WO2006058226A2 (en) 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) * 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
US7704708B2 (en) 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
US20070238169A1 (en) 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
DK1905839T4 (da) 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
DE502006006800D1 (de) 2006-09-22 2010-06-02 Wacker Chemie Ag Verfahren zur fermentativen Herstellung von Proteinen
EP1903115B1 (de) 2006-09-22 2011-03-09 Wacker Chemie AG Verfahren zur fermentativen Herstellung von Antikörpern
BRPI0717651A2 (pt) 2006-10-17 2013-12-24 Oncotherapy Science Inc Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1
CA2668001C (en) * 2006-11-02 2016-05-03 Kyowa Medex Co., Ltd. A method of immunoassaying a component to be measured in a sample containing hemoglobin
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) * 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
CN102517280A (zh) 2007-01-31 2012-06-27 菲尼克斯股份有限公司 用于提高表达的细菌前导序列
KR20080076622A (ko) 2007-02-16 2008-08-20 포항공과대학교 산학협력단 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2617827A1 (en) 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009024591A1 (en) 2007-08-20 2009-02-26 Bio-Medisinsk Innovasjon As Pvii phage display
JP4962215B2 (ja) 2007-08-28 2012-06-27 パナソニック株式会社 墨出し器の精度確認装置及び墨出し器の精度確認方法
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2520643T3 (da) 2007-12-07 2020-01-20 Miltenyi Biotec Bv & Co Kg Prøvebehandlingssystemer og -fremgangsmåder
CN101978269A (zh) 2008-01-18 2011-02-16 哈佛大学校长及研究员协会 在体液中检测疾病或病症标志的方法
ES2890729T3 (es) 2008-01-29 2022-01-21 Hutchinson Fred Cancer Res Identificación de células T CD8+ que son CD161hi y/o IL-18Rahi y que tienen una capacidad de evacuación rápida de fármacos
CN101932598B (zh) 2008-01-30 2016-12-21 皮里斯股份公司 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
DE102009018647A1 (de) 2009-04-23 2010-10-28 Osram Opto Semiconductors Gmbh Strahlungsemittierende Vorrichtung
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
WO2011053971A2 (en) 2009-11-02 2011-05-05 Fina Biosolutions, Llc Method for enhancing the sensitivity of antibody based assays
MX2012005168A (es) 2009-11-05 2012-06-08 Genentech Inc Metodos y composicion para secrecion de polipeptidos heterologos.
WO2011062862A1 (en) 2009-11-17 2011-05-26 Centocor Ortho Biotech Inc. Improved bacterial membrane protein secrection
US20120321665A1 (en) 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
US9891148B2 (en) 2010-02-09 2018-02-13 Douglas T. Gjerde Method and apparatus for pipette tip columns
US9637719B2 (en) 2013-12-06 2017-05-02 Douglas T. Gjerde Devices and methods for purification of biological cells
US9242244B2 (en) 2010-02-09 2016-01-26 Douglas T. Gjerde Method and apparatus for pipette tip columns
US9370732B2 (en) 2013-02-15 2016-06-21 Douglas T. Gjerde Methods for purifying biological cells
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
JP5665021B2 (ja) 2010-03-08 2015-02-04 国立大学法人東京農工大学 融合ｍｈｃ分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体
EP2585579A2 (en) 2010-06-23 2013-05-01 Stobbe Tech A/s Device and method for industrial cultivation of cells
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
EP3376225A1 (en) * 2010-08-06 2018-09-19 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
JP5840857B2 (ja) 2011-04-08 2016-01-06 国立大学法人 東京大学 細胞傷害性ｔ細胞誘導用組成物
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
WO2013038272A2 (en) 2011-09-13 2013-03-21 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
WO2013062365A2 (ko) 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
WO2014011996A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
CA2891820A1 (en) 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
BR112015017994A2 (pt) 2013-01-31 2017-07-11 Glaxo Group Ltd método para produzir uma proteína recombinante, método para clarificar uma coleta microbiana, e, coleta modificada de célula de escherichia coli
US10220332B2 (en) 2013-02-15 2019-03-05 Douglas T. Gjerde Columns for isolation, detection and use of biological cells
US10107729B2 (en) 2013-02-15 2018-10-23 Douglas T. Gjerde Isolation, detection and use of biological cells
US9920294B2 (en) 2013-02-15 2018-03-20 Douglas T. Gjerde Devices and methods for purification, detection and use of biological cells
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
MX386422B (es) 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
MY184699A (en) 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CA2946222C (en) 2014-04-24 2020-12-22 Miltenyi Biotec Gmbh Method for automated generation of genetically modified t cells
SG11201608744VA (en) 2014-04-25 2016-11-29 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
AU2015254588B2 (en) 2014-04-30 2020-05-21 Iba Gmbh Method of isolating a target cell
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016012623A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CN108474002B (zh) 2015-10-22 2023-05-23 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
EP3440191A4 (en) 2016-04-07 2019-12-11 Bluebird Bio, Inc. CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
SG11201909931PA (en) 2017-04-27 2019-11-28 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US20190247846A1 (en) 2018-02-09 2019-08-15 Chris Suh Method and Apparatus for Pipette Tip Columns
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
JP7582940B2 (ja) 2018-10-31 2024-11-13 ジュノ セラピューティクス ゲーエムベーハー 細胞の選択および刺激のための方法ならびにそのための装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255004A1 (en) * 2006-11-15 2008-10-16 Invitrogen Dynal As Methods of reversibly binding a biotin compound to a support

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU YE ET AL, "Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells", ANALYTICAL CHEMISTRY, 2009, vol. 81, pages 7436 -7442 *

Also Published As

Publication number Publication date
WO2013124474A2 (en) 2013-08-29
EP4545964A2 (en) 2025-04-30
AU2021282451A1 (en) 2022-01-06
JP2023016981A (ja) 2023-02-02
IN2014DN06475A (enExample) 2015-06-12
EP4545964A3 (en) 2025-10-01
EP2817625A2 (en) 2014-12-31
US20190226951A1 (en) 2019-07-25
AU2019200178B2 (en) 2021-09-09
RU2746407C1 (ru) 2021-04-13
HK1202335A1 (en) 2015-09-25
US20250020556A1 (en) 2025-01-16
US12135265B2 (en) 2024-11-05
CA2865033C (en) 2021-11-02
US20190234844A1 (en) 2019-08-01
CN104254780B (zh) 2017-04-12
SG11201404991YA (en) 2014-09-26
EP2817625B1 (en) 2025-01-01
US20150024411A1 (en) 2015-01-22
CN106940268A (zh) 2017-07-11
AU2021282451B2 (en) 2025-02-20
JP7710427B2 (ja) 2025-07-18
AU2019200178A1 (en) 2019-01-31
CN106940268B (zh) 2021-09-21
AU2025200426A1 (en) 2025-02-27
WO2013124474A3 (en) 2013-12-05
US12066365B2 (en) 2024-08-20
AU2013224027A1 (en) 2014-10-02
US10228312B2 (en) 2019-03-12
JP6362543B2 (ja) 2018-07-25
JP6857626B2 (ja) 2021-04-14
CN104254780A (zh) 2014-12-31
ES3011307T3 (en) 2025-04-07
CA2865033A1 (en) 2013-08-29
JP7192014B2 (ja) 2022-12-19
JP2018108103A (ja) 2018-07-12
JP2021090471A (ja) 2021-06-17
JP2015512621A (ja) 2015-04-30
SG10201606970UA (en) 2016-10-28

Similar Documents

Publication Publication Date Title
AU2021282451B2 (en) Chromatographic isolation of cells and other complex biological materials
AU2015254588B2 (en) Method of isolating a target cell
AU2021213439B2 (en) Methods of isolating a biological entity
HK1202335B (en) Chromatographic isolation of cells and other complex biological materials

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)